Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Inhibition of melanoma metastasis by dual-peptlde PLGA NPS

Full text
Arruda, Denise Costa [1] ; de Oliveira, Thais Dolzany [1] ; Fukuda Cursino, Patricia Harume [2] ; Carneiro Maia, Vera Susana [3] ; Berzaghi, Rodrigo [4] ; Travassos, Luiz R. [4] ; Tada, Dayane Batista [2]
Total Authors: 7
[1] Univ Mogi das Cruzes, Integrated Grp Biotechnol, Mogi das Cruzes, SP - Brazil
[2] Univ Fed Sao Paulo, Inst Sci & Technol, Sao Jose Dos Campos, SP - Brazil
[3] Recepta Biopharma, BR-04533 Sao Paulo, SP - Brazil
[4] Univ Fed Sao Paulo UNIFESP, Expt Oncol Unit UNONEX, Sao Paulo, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Biopolymers; v. 108, n. 5 SEP 2017.
Web of Science Citations: 1

Despite the positive results observed in vitro and in vivo, clinical trials with bioactive peptides are generally hampered by their fast degradation in the biological system. Two bioactive peptides, P20 (CSSRTMHHC and the combined peptide C (CVNHPAFACGYGHTMYYHHYQHHL) have been identified as anticancer therapeutics. Combined peptide C consists of peptide C (CVNHPAFAC), a tumor-homing peptide, conjugated to the antiangiogenic peptide HTMYYHHYQHHL with a GYG. In this work, PLGA NPs with peptide C were applied as a dual-peptide carrier for application in cancer therapy. Peptide P20 was loaded into the NPs and combined peptide C was conjugated to the NPs surface. These NPs were evaluated as a therapeutic system to treat metastatic melanoma. in vivo assays showed that P20 encapsulation in PLGA NPs enhanced its antitumor activity. The inhibitory activity of P20-PLGANPs was similar to the activity of non-encapsulated P20 in a dose fivefold higher. The inhibitory activity was even higher when P20PLGA NPs were functionalized with combined peptide C. P20PLGAPepC NPs reduced in 28% the number of lung nodules in a syngeneic model of metastatic melanoma as compared to untreated animals. Additionally to the better tumor targeting and the in situ release of P20, it is expected that the therapeutic efficiency of the dual-peptide PLGA NPs was further enhanced by a synergistic effect between P20 and combined peptide C. Our encouraging results showed that by enabling the co-delivery of two peptides and promoting tumor targeting, PLGA NPs coupled with peptide C is a promising platform for peptide-based cancer therapy. (AU)

FAPESP's process: 11/23895-8 - Characterization and control of cellular internalization process of nanoparticles
Grantee:Dayane Batista Tada
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 15/05980-9 - Antitumoral activity induced by peptides from transcription factor Brn-2 in murine and human melanoma
Grantee:Denise Costa Arruda
Support Opportunities: Regular Research Grants
FAPESP's process: 10/51423-0 - Bioactive peptides and peptidases: biological and immunobiological activities in infectious diseases and cancer
Grantee:Luiz Rodolpho Raja Gabaglia Travassos
Support Opportunities: Research Projects - Thematic Grants